A United Kingdom study evaluating changes of quality of life for patients with GLP1-RA demonstrated that the therapy significantly reduced the Hospital Anxiety and Depression Scale (HADS) scores, compared with insulin-treated patients. The gene discussed is GLP1R; the disease is depressive symptom measurement.